Basilea Pharmaceutica AG
Records under this name other than the patents Basilea Pharmaceutica AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 10 patents it holds.
Back to Basilea Pharmaceutica AG
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,163,034 | Crystalline (6R,7R)-7-{2-(5-amino-[1,2,4] thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1′-tert-butoxycarbonyl-2-oxo-[1,3′]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,865,697 | Crystalline (6R,7R)-7-{2-(5-amino-[1,2,4] thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1′-tert-butoxycarbonyl-2-oxo-[1,3′]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,995,754 | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles Lapsed on the fee record Ended Jun 12, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 12, 2026 | From the USPTO record |
| US 9,970,938 | Use of BUBR1 as a Biomarker of Drug Response to Furazanobenzimidazoles Formerly held Lapsed on the fee record Ended May 15, 2026 · High confidence | Lapsed on the fee record | Ended May 15, 2026 | High confidence |
| US 6,812,238 | N-substituted carbamoyloxyalkyl-azolium derivatives Formerly held Term ended Term ended Oct 31, 2025 · From the USPTO record | Term ended | Term ended Oct 31, 2025 | From the USPTO record |
| US 8,697,122 | Formulation for Retinoid-Containing Soft Gelatin Capsules Formerly held Term ended Ended no later than Feb 19, 2025 · Medium confidence | Term ended | Ended no later than Feb 19, 2025 | Medium confidence |
| US 8,093,377 | Cephalosporin in crystalline form Term ended Term ended Jan 17, 2025 · From the USPTO record | Term ended | Term ended Jan 17, 2025 | From the USPTO record |
| US 9,476,889 | Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles Lapsed on the fee record Ended Oct 25, 2024 · From the USPTO record | Lapsed on the fee record | Ended Oct 25, 2024 | From the USPTO record |
| US 7,531,650 | Cephalosporin salts in crystalline form Term ended Term ended Oct 21, 2024 · From the USPTO record | Term ended | Term ended Oct 21, 2024 | From the USPTO record |
| US 9,084,823 | Formulation For Retinoid-Containing Soft Gelatin Capsules Formerly held Term ended Ended no later than Oct 5, 2024 · Low confidence | Term ended | Ended no later than Oct 5, 2024 | Low confidence |